In light of the ongoing HIV epidemic in Thailand, they discussed a need for more affordable HIV treatments in Thailand and other resource limited settings, and the reluctance on the part of the pharmaceutical companies and other sponsors to move HIV related clinical research to areas where HIV is most prevalent.